Shanghai Junshi Biosciences Co., Ltd. is a pioneering biopharmaceutical company headquartered in Shanghai, China, with a mission to deliver innovative therapies to address some of the world’s most challenging diseases. Established in 2012, Junshi Biosciences has become a leader in the development of immuno-oncology and biologic drugs, driven by its commitment to scientific excellence and patient-centric innovation.
Company Overview
Junshi Biosciences operates with a focus on R&D, clinical development, manufacturing, and commercialization of novel therapies across oncology, autoimmune, metabolic, infectious, and neurological diseases. As a publicly listed company on both the Hong Kong Stock Exchange (HKEX: 1877) and the Shanghai STAR Market (688180), Junshi embodies transparency, global ambition, and rigorous compliance standards.
CEO: Dr. Ning Li
Global Employees: Over 2,000
Research Centers: Shanghai, Suzhou, Beijing, and San Francisco Bay Area (USA)
Manufacturing Facilities: Two GMP-certified biologics manufacturing sites in China
Core Therapeutic Areas and Key Products
Oncology
- Toripalimab (TUOYI®): China's first domestically developed anti-PD-1 monoclonal antibody approved for multiple indications including melanoma and nasopharyngeal carcinoma.
- JS108 (Trop2 ADC): An antibody-drug conjugate targeting Trop2-expressing tumors.
- JS101 (Pan-CDK): A novel therapy targeting cyclin-dependent kinases in solid tumors.
Autoimmune Disorders
- Adalimumab (JUNMAIKANG®): A biosimilar of Humira for rheumatoid arthritis and other inflammatory conditions.
- JS005 (IL-17A) and UBP1213 (BLyS): Designed for psoriasis and systemic lupus erythematosus respectively.
Metabolic Diseases
- JS002 (PCSK9): A monoclonal antibody for cholesterol management.
- JS103 (Uricase): Treatment for chronic gout.
- JS401 (ANGPTL3): Targets lipid metabolism disorders.
Neurological Disorders
- JS010 (CGRP): A monoclonal antibody developed for migraine prevention.
Infectious Diseases
- Etesevimab (JS016): A COVID-19 monoclonal antibody developed in partnership with Eli Lilly, granted Emergency Use Authorization in multiple countries.
- Deuremidevir Hydrobromide (VV116): An oral antiviral drug with broad-spectrum activity.
Research and Development
Junshi is recognized for its strong R&D capabilities:
- More than 30 innovative drug candidates in the pipeline
- Annual R&D investment exceeds 40% of total revenue
- Collaborations with top-tier institutions including Eli Lilly, Coherus BioSciences, and Impact Therapeutics
- Comprehensive clinical trial coverage across over 20 countries
Manufacturing and Compliance
Junshi operates two large-scale GMP-compliant biologics manufacturing plants, equipped with:
- Single-use bioreactor systems
- Automated fill-finish lines
- Capacity exceeding 30,000 liters of bioreactor volume
- Compliance with CFDA, EMA, and US FDA quality standards
Financial and Market Performance
- Listed Market Cap: Approx. USD 6 billion (as of 2024)
- 2023 Revenue: Over RMB 4.8 billion
- Strong pipeline-to-market conversion with multiple NDA/BLA approvals in China and abroad
Global Partnerships
Strategic alliances include:
- Eli Lilly (Co-development of Etesevimab)
- Coherus BioSciences (Commercialization of Toripalimab in the U.S.)
- Impact Therapeutics (Oncology pipeline collaboration)
These partnerships underscore Junshi’s international credibility and ambition to enter highly regulated markets.
Certifications and Recognitions
- ISO 13485: Medical Device Quality
- CFDA, EMA, and FDA facility compliance
- Frost & Sullivan Innovation Award for Best Pipeline in Oncology (2022)
Digital Presence and Outreach
- Official Website: junshipharma.com
- LinkedIn: Engages with investors, healthcare professionals, and R&D communities
- YouTube Channel: Showcases product launches, trial results, and educational content
Corporate Vision
Junshi Biosciences aims to become a global biotech powerhouse, delivering life-saving therapeutics from lab bench to bedside, with a focus on:
- Pioneering immuno-oncology
- Expanding access to biologics in emerging markets
- Fostering cross-border R&D collaboration
Shanghai Junshi Biosciences Co., Ltd. continues to redefine the boundaries of innovation in Chinese biotech, standing at the forefront of science-driven solutions for global health.
